Our study highlights that BET inhibition reduced both constitutively active canonical NFκB as well as STAT signaling, indicating that BCL2A1 expression is regulated by a complex network of survival signaling pathways in ABC and GCB DLBCL cell lines. The gene discussed is BCL2A1; the disease is diffuse large B-cell lymphoma.